Literature DB >> 1934373

Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis.

A M Zeiher1, H Drexler, H Wollschläger, H Just.   

Abstract

BACKGROUND: The vascular endothelium is capable of regulating tissue perfusion by the release of endothelium-derived relaxing factor to modulate vasomotor tone of the resistance vasculature. METHODS AND
RESULTS: To test whether atherosclerosis is associated with a functional abnormality of endothelium-mediated microvascular relaxation affecting coronary blood flow regulation, we compared coronary blood flow responses with cold pressor testing with the response of the coronary vasculature to acetylcholine (an endothelium-dependent vasodilator) and to papaverin (a direct dilator of vascular smooth muscle) in 12 normal control patients and in 19 patients with non-flow-limiting epicardial atherosclerosis (CAD). The drugs were subselectively infused into the left anterior descending coronary artery via a Doppler catheter, and the response in coronary blood flow was assessed by measuring intracoronary blood flow velocity and cross-sectional arterial area (quantitative angiography). Coronary vascular resistance decreased in all normal control patients by -24.1 +/- 5.5% (mean +/- SD) during the cold pressor test, whereas the CAD patients demonstrated a variable coronary vascular resistance response to cold pressor testing despite comparable changes in the rate-pressure product. The slopes of the acetylcholine dose-blood flow response (percent change in coronary blood flow/dosage of acetylcholine) were significantly reduced in the CAD patients with 38.5 +/- 24.8 compared with the normal patients (80.8 +/- 28.1; p less than 0.001). Although coronary blood flow responses to papaverin were slightly but significantly (p less than 0.05) reduced in the CAD patients, the response to the endothelium-dependent dilator acetylcholine was considerably out of proportion to the papaverin response in these patients compared with the normal patients. The capacity of the coronary system to increase blood flow in response to acetylcholine expressed as relative proportion of the maximal papaverin response was 52.5 +/- 18.2% in the normal control patients but only 33.6 +/- 23.6% in the CAD patients (p less than 0.025 versus normals). There was a significant negative correlation (r = -0.69; p less than 0.0001) between cold pressor test-induced changes in coronary vascular resistance and the capacity of the coronary system to increase blood flow in response to acetylcholine.
CONCLUSIONS: Early stages of epicardial atherosclerosis are associated with an impairment in endothelium-dependent dilation of the coronary microvasculature, indicating that the pathophysiological consequences of atherosclerosis may extend into the human coronary microcirculation. The correlation between cold pressor test-induced coronary vascular resistance changes and the extent of endothelial dysfunction suggests a relation between endothelial function of the microvasculature and coronary blood flow regulation during sympathetic stimulation associated with increased myocardial work.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1934373     DOI: 10.1161/01.cir.84.5.1984

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  101 in total

1.  Beyond the cholesterol profile: monitoring therapeutic effectiveness of statin therapy.

Authors:  R G Schwartz
Journal:  J Nucl Cardiol       Date:  2001 Jul-Aug       Impact factor: 5.952

Review 2.  Endothelial dysfunction and coronary artery disease: assessment, prognosis, and treatment.

Authors:  Yasushi Matsuzawa; Amir Lerman
Journal:  Coron Artery Dis       Date:  2014-12       Impact factor: 1.439

3.  Endothelial dysfunction in atherosclerotic mice: improved relaxation by combined supplementation with L-arginine-tetrahydrobiopterin and enhanced vasoconstriction by endothelin.

Authors:  J Jiang; G Valen; S Tokuno; P Thorén; J Pernow
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

Review 4.  The value of quantitative myocardial perfusion imaging with positron emission tomography in coronary artery disease.

Authors:  W Wijns; P G Camici
Journal:  Herz       Date:  1997-04       Impact factor: 1.443

5.  Assessment of coronary flow reserve and microcirculation: a clinical perspective.

Authors:  Roxana Campisi; Marcelo F Di Carli
Journal:  J Nucl Cardiol       Date:  2004 Jan-Feb       Impact factor: 5.952

6.  Regional myocardial perfusion defects during exercise, as assessed by three dimensional integration of morphology and function, in relation to abnormal endothelium dependent vasoreactivity of the coronary microcirculation.

Authors:  T H Schindler; E Nitzsche; N Magosaki; I Brink; M Mix; M Olschewski; U Solzbach; H Just
Journal:  Heart       Date:  2003-05       Impact factor: 5.994

7.  Early insights of cardiac risk and treatment response with quantitative PET monitoring of coronary-specific endothelial dysfunction and myocardial perfusion reserve.

Authors:  Ronald G Schwartz
Journal:  J Nucl Cardiol       Date:  2010-12       Impact factor: 5.952

8.  Quantitative analysis of coronary endothelial function with generator-produced 82Rb PET: comparison with 15O-labelled water PET.

Authors:  Keiichiro Yoshinaga; Osamu Manabe; Chietsugu Katoh; Li Chen; Ran Klein; Masanao Naya; Robert A deKemp; Kathryn Williams; Rob S B Beanlands; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-13       Impact factor: 9.236

9.  Improved cardiac risk assessment with noninvasive measures of coronary flow reserve.

Authors:  Venkatesh L Murthy; Masanao Naya; Courtney R Foster; Jon Hainer; Mariya Gaber; Gilda Di Carli; Ron Blankstein; Sharmila Dorbala; Arkadiusz Sitek; Michael J Pencina; Marcelo F Di Carli
Journal:  Circulation       Date:  2011-10-17       Impact factor: 29.690

10.  Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis.

Authors:  A A Quyyumi; N Dakak; N P Andrews; S Husain; S Arora; D M Gilligan; J A Panza; R O Cannon
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.